The global intratumoral cancer therapies market size was valued at USD 208.70 Billion in 2025. The market is expected to grow at a CAGR of 10.00% during the forecast period of 2026-2035, reaching a value of USD 541.31 Billion by 2035. The market growth is driven by the increasing adoption of localized treatment approaches and innovations in immunotherapy, enhancing efficacy and reducing systemic side effects. Advancements in personalized medicine, including tumor-specific targeting and combination therapies, are expected to propel market growth during the forecast period. Rising clinical trials and supportive regulatory frameworks further support expansion.
Base Year
Historical Period
Forecast Period
The demand for intratumoral cancer therapies is influenced by the rising preference for combination therapies and personalised treatment to combat the increasing incidence of cancer.
In April 2024, the phase I clinical trial of SYNC-T, an investigational intratumoral therapy, demonstrated significant response rates and minimal toxicity in the management of metastatic castrate-resistant prostate cancer. Increased R&D initiatives are expected to boost the market growth positively.
North America is expected to have the largest market share because of the well-developed healthcare system and high investments in medical technology, while Asia Pacific is expected to register a high growth rate in the forecast period.
Compound Annual Growth Rate
10%
Value in USD Billion
2026-2035
*this image is indicative*
Cancer is a leading cause of death that originates from cells multiplying and invading other tissues and organs. Intratumoral therapy involves deploying antibodies into the tumor mass to trigger and strengthen an antitumor immune response. It stimulates local immunity against the tumor by utilizing it as the source of its vaccine. It also stimulates adaptive, polyclonal immunity against clinically established tumor-specific antigens (TSA) or tumor-associated antigens (TAA).
Rising Prevalence of Cancer Fuels the Market Growth
Rising cases of breast, lung, colorectal, and prostate, among others, are prompting the need for novel and effective treatments. For instance, the American Cancer Society estimates 152,810 new cases of colorectal cancer in 2024. According to their estimates, 81,540 men and 71,270 women will be diagnosed with the disease. Around 106,590 cases will be colon cancer, and 46,220 cases will be diagnosed as rectal cancer, respectively. Accordingly, a sustained rise in cancer rates is expected to fuel the market for these revolutionary treatment approaches.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
In April 2024 , the American Association for Cancer Research (AACR) Annual Meeting 2024 highlighted the potential of SYNC-T, an investigational therapy that applies device-induced vaccination at the tumor site with concurrent intratumoral administration of a multitarget biologic agent for managing metastatic castrate-resistant prostate cancer. In a phase I clinical trial, the drug achieved an objective response in 11 out of 13 evaluable patients and had only mild to moderate toxicity in patients, which was lower than intravenous immunotherapies.
In January 2022 , Bristol-Myers Squibb announced that the Japanese Ministry of Health, Labour, and Welfare approved Abecma, which is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for use in adults with relapsed and refractory multiple myeloma who have undergone at least three prior therapies. Abecma was the first licensed CAR T cell therapy for treating R/R multiple myeloma in Japan.
The Expert Market Research’s report titled “Global Intratumoral Cancer Therapies Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Monoclonal Antibodies Hold a Substantial Market Share Based on the Type
Based on type, the market is divided into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. Among these, monoclonal antibodies are expected to dominate the market as they have higher specificity towards tumor tissues, thus, while destroying malignant cells, they do not affect the systemically healthy cells. Monoclonal antibodies have become the gold standard in precision medicine, leading to more clinical studies of targeted therapies.
Market Segmentation by Application Set to Witness Substantial Growth
Based on application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. Among these, lung cancer is expected to dominate the market due to high incidence of the disease. Intratumoral therapies are increasing in popularity as they enable the delivery of high concentrations of therapeutic agents to the tumor mass with minimal systemic toxicity. This approach is therefore valuable as an alternative to traditional therapies, fostering the advancements of new personalized cancer treatments and expanding the array of targeted therapy options for other cancers.
Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Of these regions, North America is expected to dominate, owing to its developed healthcare system, high spending on healthcare, and its leading investment in modern, advanced medical technologies.
Due to the increasing incidence of cancer, better infrastructure, and focus on research, the fastest growth is expected to be seen in the Asia-Pacific region. Countries like China, Japan, and India are expected to lead the market share in the region.
The key features of the market report include patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
The company was established in 1980 and is based in California, USA. It offers T-VEC (talimogene laherparepvec), an oncolytic viral therapy genetically engineered for melanoma treatment.
It is a UK-based company and has a well-established portfolio of immune-oncology assets, including combinations that can be delivered intratumorally.
This company was founded in 1863 and is headquartered in Germany. Some of the intratumoral cancer therapy activities consist of developing new drug delivery systems coupled with combination therapy to boost the effectiveness of their current cancer treatment drugs.
It was founded in 1887 and headquartered in New York, USA. Opdivo and Yervoy are the two main products provided by the company, while these agents are mainly used in combination with other products for increased effectiveness.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly Company, Cybrexa, and Novocure GmbH, among others.
Kindly note that this only represents a partial list of companies. The complete list will be provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share